ClinicalTrials.gg
Not yet recruitingNCT07839884Updated Sep 24, 2026

A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time

A Phase 3 interventional study of Tilrekimig in Moderate to Severe Chronic Obstructive Pulmonary Disease, sponsored by Pfizer. Not yet recruiting. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,360
Allocation
Not applicable
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Pfizer.

Planned enrollment
Largest of 19
1,360 · median 105
Started
2026
with 1 other
Phase 3
2 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 3, and was the 22nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer, or all of them as a file.
02

Study summary

A Continuation Study of Tilrekimig in Adults with Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About this Medicine when Used for a Long Period of Time.

Read the detailed description

C4531015 is a multicenter, open-label extension study designed to evaluate the longer-term safety and tolerability of tilrekimig in eligible participants with chronic obstructive pulmonary disease (COPD) who have participated in and completed the applicable requirements of the parent study, C4531031.

Participants who complete the protocol-defined parent-study period may be considered for enrollment in C4531015. Before entering the extension study, participants must provide informed consent, satisfy all C4531015 eligibility criteria, and be considered appropriate for continued study treatment by the investigator. Participation in C4531031 does not automatically establish eligibility for the extension study.

All enrolled participants will receive open-label tilrekimig according to the dose, route of administration, and treatment schedule specified in the C4531015 protocol. Participants may continue protocol-permitted background COPD maintenance therapy. Use of concomitant and rescue medications will be managed according to the protocol.

The study will primarily characterize the safety and tolerability of longer-term exposure to tilrekimig. Safety monitoring will include the collection of adverse events (AEs), serious adverse events (SAEs), adverse events leading to treatment interruption or discontinuation, and other protocol-defined safety events. Participants will also undergo clinical laboratory testing, vital-sign assessments, physical examinations, and other safety evaluations at scheduled study visits.

Additional protocol-defined assessments may be conducted to characterize COPD-related clinical outcomes and the effects of continued treatment. These may include evaluation of COPD exacerbations, respiratory symptoms, lung function, health status, participant-reported outcomes (PROs), healthcare resource utilization, pharmacokinetics (PK), immunogenicity, biomarkers, or other exploratory measures, as applicable. These assessments are intended to provide supportive information and should not be interpreted as demonstrating that tilrekimig is safe or effective.

Participants will attend study visits according to the protocol Schedule of Activities (SoA). At these visits, investigators will assess continued eligibility, treatment adherence, changes in health status, AEs, concomitant medications, COPD-related events, and the results of required clinical and laboratory evaluations.

Participants may discontinue study intervention because of an AE, pregnancy, use of prohibited medication, lack of compliance with protocol requirements, an investigator or sponsor decision, withdrawal of consent, or another protocol-defined reason. Participants who discontinue study intervention may be asked to complete applicable early-discontinuation and safety follow-up assessments.

The study may provide eligible participants transitioning from C4531031 with continued access to investigational treatment while allowing additional safety and clinical information to be collected over a longer treatment period. Tilrekimig remains investigational, and participation in the study does not guarantee that an individual participant will experience clinical benefit.

03

Conditions studied

  • Moderate to Severe Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who completed parent study C4531031.
  • Individuals of must be willing to use a highly effective method of .

Exclusion criteria

EXCLUSION CRITERIA

  • Ongoing safety-significant AE.
  • Parent-study SAE incompatible with continued participation.
  • Medical, laboratory, psychiatric, or behavioral condition that increases risk or interferes with study participation.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,360 participants (estimated)

Study arms

  • Experimental
    Tilrekimig (PF-07275315)

    Tilrekimig (PF-07275315) subcutaneous injection (sc)

    Drug: Tilrekimig

Interventions

  • SC injection

    Also known as: PF-07275315

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events During Treatment Period 1 (TP1)

    Number and percentage of participants with treatment-emergent adverse events. An adverse event is considered treatment-emergent if it begins or increases in severity following initiation of study intervention. Events will be summarized by severity and other protocol-defined characteristics

    Time frame: Up to 60 weeks

  2. Number of Participants With Treatment-Emergent Serious Adverse Events During Treatment Period 1

    Number and percentage of participants with treatment-emergent serious adverse events. Serious adverse events are events that meet one or more of the protocol-defined seriousness criteria.

    Time frame: Up to 60 weeks

  3. Number of Participants With Treatment-Emergent Adverse Events Leading to Permanent Discontinuation of Study Intervention During Treatment Period 1

    Number and percentage of participants with treatment-emergent adverse events that lead to permanent discontinuation of tilrekimig.

    Time frame: Up to 60 weeks

  4. Number of Participants With Clinically Significant Laboratory Abnormalities During Treatment Period 1

    Number and percentage of participants with protocol-defined clinical abnormalities in laboratory values and vitals signs. Laboratory assessments include protocol-required hematology and blood chemistry evaluations. Abnormal laboratory findings will be evaluated according to protocol-defined criteria and investigator assessment of clinical significance. Vital-sign assessments include blood pressure, pulse rate, respiratory rate, temperature, and oxygen saturation measured by pulse oximetry.

    Time frame: Up to 60 weeks

Secondary outcomes

  1. Annualized Rate of Moderate or Severe COPD Exacerbations During Treatment Period 1

    Unadjusted annualized rate of adjudicated moderate or severe exacerbations of COPD. A moderate exacerbation is an acute worsening of COPD requiring systemic corticosteroids and/or antibiotics. A severe exacerbation is an acute worsening of COPD requiring hospital admission for at least 24 hours.

    Time frame: 52 Weeks

  2. Annualized Rate of Severe COPD Exacerbations During Treatment Period 1

    Unadjusted annualized rate of adjudicated severe COPD exacerbations. A severe COPD exacerbation is an acute worsening of COPD requiring hospital admission for at least 24 hours.

    Time frame: 52 Weeks

  3. Annualized Rate of COPD Exacerbations Requiring an Emergency Department Visit and/or Hospitalization During Treatment Period 1

    Unadjusted annualized rate of COPD exacerbations requiring an emergency department visit and/or hospitalization.

    Time frame: 52 Weeks

  4. Cumulative Number of Moderate or Severe COPD Exacerbations During Treatment Period 1

    Mean cumulative number of adjudicated moderate or severe COPD exacerbation events over time.

    Time frame: 52 Weeks

  5. Cumulative Number of Severe COPD Exacerbations During Treatment Period 1

    Mean cumulative number of adjudicated severe COPD exacerbation events over time.

    Time frame: 52 Weeks

  6. Time to First Moderate or Severe COPD Exacerbation During Treatment Period 1

    Treatment Period 1Time from initiation of C4531015 study intervention to the first adjudicated moderate or severe COPD exacerbation. The probability of an event will be estimated using the Kaplan-Meier method.

    Time frame: 52 Weeks

  7. Change From Parent-Study Baseline in Pre- and Post-Bronchodilator Lung Function During Treatment Period 1

    Change from the parent-study baseline at each scheduled assessment in the following spirometry parameters: pre-bronchodilator FEV1, post-bronchodilator FEV1, pre-bronchodilator FEV1/FVC ratio, and post-bronchodilator FEV1/FVC ratio. FEV1 is the forced expiratory volume in 1 second, and FVC is the forced vital capacity. Spirometry will be performed using standardized equipment and procedures. Post-bronchodilator measurements will be obtained following administration of a short-acting bronchodilator in accordance with the protocol. FEV1 will be reported in liters, and FEV1/FVC will be reported as a ratio.

    Time frame: 52 Weeks

  8. Change From Parent-Study Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score During Treatment Period 1

    Change from the parent-study baseline in SGRQ total score at each scheduled assessment. The SGRQ contains 50 items assessing symptoms, activity, and impacts on daily life. Total scores range from 0 to 100, with lower scores indicating better quality of life.

    Time frame: 52 Weeks

  9. Change From Parent-Study Baseline in COPD Assessment Test (CAT) Total Score During Treatment Period 1

    Change from the parent-study baseline in CAT total score at each scheduled assessment. The CAT contains 8 items scored from 0 to 5. The total score ranges from 0 to 40, with higher scores indicating worse health.

    Time frame: 52 Weeks

  10. Change From Parent-Study Baseline in Weekly Use of Short-Acting Bronchodilator Medication During Treatment Period 1

    Change from the parent-study baseline in weekly use of short-acting bronchodilator medication at each protocol-specified assessment. Use of the bronchodilator administered solely for post-bronchodilator spirometry is excluded.

    Time frame: 52 Weeks

  11. Percentage of Participants Achieving at Least a 4-Point Improvement From Parent-Study Baseline in SGRQ Total Score During Treatment Period 1

    Percentage of participants classified as SGRQ responders at each scheduled assessment. A responder is a participant with an improvement of at least 4 points from the parent-study baseline in SGRQ total score. An improvement corresponds to a reduction in the total score.

    Time frame: 52 Weeks

  12. Percentage of Participants Achieving at Least a 2-Point Improvement From Parent-Study Baseline in CAT Total Score During Treatment Period 1

    Percentage of participants classified as CAT responders at each scheduled assessment. A responder is a participant with an improvement of at least 2 points from the parent-study baseline in CAT total score. An improvement corresponds to a reduction in the total score.

    Time frame: 52 Weeks

  13. COPD Exacerbations in Participants With Parent-Study Baseline Blood Eosinophil Count ≥300 Cells/µL

    Unadjusted annualized rate of adjudicated moderate or severe COPD exacerbations in participants with a blood eosinophil count of at least 300 cells/µL at the parent-study baseline

    Time frame: 52 Weeks

  14. Lung Function in Participants With Parent-Study Baseline Blood Eosinophil Count ≥300 Cells/µL

    Change from parent-study baseline in pre-bronchodilator FEV1; change from parent-study baseline in post-bronchodilator FEV1 in participants with a blood eosinophil count of at least 300 cells/µL at the parent-study baseline

    Time frame: 52 Weeks

  15. Annualized Rate of Moderate or Severe COPD Exacerbations Through End of Study

    Unadjusted annualized rate of adjudicated moderate or severe COPD exacerbations over the participant's full period of study participation.

    Time frame: Up to 36 months

  16. Annualized Rate of Severe COPD Exacerbations Through End of Study

    Unadjusted annualized rate of adjudicated severe COPD exacerbations over the participant's full period of study participation.

    Time frame: Up to 36 months

  17. Annualized Rate of COPD Exacerbations Requiring an Emergency Department Visit and/or Hospitalization Through End of Study

    Unadjusted annualized rate of COPD exacerbations requiring an emergency department visit and/or hospitalization.

    Time frame: Up to 36 months

  18. Cumulative Number of Moderate or Severe COPD Exacerbations Through End of Study

    Mean cumulative number of adjudicated moderate or severe COPD exacerbation events over time.

    Time frame: Up to 36 months

  19. Cumulative Number of Severe COPD Exacerbations Through End of Study

    Mean cumulative number of adjudicated severe COPD exacerbation events over time.

    Time frame: Up to 36 months

  20. Change From Parent-Study Baseline in COPD Assessment Test total score During Treatment Period 1 in participants with Parent-Study Baseline Blood Eosinophil Count ≥300 Cells/µL

    Change from parent-study baseline in CAT total score in participants with a blood eosinophil count of at least 300 cells/µL at the parent-study baseline

    Time frame: 52 Weeks

  21. Change From Parent-Study Baseline in Pre- and Post-Bronchodilator Lung Function Through End of Study

    Change from the corresponding parent-study baseline at each protocol-specified assessment in the following spirometry parameters: pre-bronchodilator FEV1, post-bronchodilator FEV1, pre-bronchodilator FEV1/FVC ratio, and post-bronchodilator FEV1/FVC ratio. FEV1 is forced expiratory volume in 1 second, and FVC is forced vital capacity. Spirometry will be performed using standardized equipment and procedures. Post-bronchodilator measurements will be obtained after administration of a short-acting bronchodilator in accordance with the protocol. FEV1 will be reported in liters and FEV1/FVC as a ratio.

    Time frame: Up to 36 months

  22. Change From Parent-Study Baseline in SGRQ Total Score After Week 52

    Change from the parent-study baseline in SGRQ total score at each scheduled assessment after Week 52 of TP1. Scores range from 0 to 100, with lower scores indicating better quality of life.

    Time frame: Up to 36 months

  23. Change from the parent-study baseline in CAT total score at each scheduled assessment after Week 52 of TP1

    Change from the parent-study baseline in CAT total score at each scheduled assessment after Week 52 of TP1. Scores range from 0 to 40, with higher scores indicating worse health.

    Time frame: Up to 36 months

  24. Change From Parent-Study Baseline in Saint George's Respiratory Questionnaire total score Total Score During Treatment Period 1 in participants with Parent-Study Baseline Blood Eosinophil Count ≥300 Cells/µL

    Change from parent-study baseline in Saint George's Respiratory Questionnaire total score in participants with a blood eosinophil count of at least 300 cells/µL at the parent-study baseline

    Time frame: 52 Weeks

  25. Change From Parent-Study Baseline in Weekly Use of Short-Acting Bronchodilator Medication After Week 52

    Change from the parent-study baseline in weekly use of short-acting bronchodilator medication at each scheduled assessment after Week 52 of TP1.

    Time frame: Up to 36 months

  26. Percentage of Participants Achieving at Least a 4-Point Improvement From Parent-Study Baseline in SGRQ Total Score After Week 52

    Percentage of participants with an improvement of at least 4 points from the parent-study baseline in SGRQ total score at each scheduled assessment after Week 52.

    Time frame: Up to 36 months

  27. Percentage of Participants Achieving at Least a 2-Point Improvement From Parent-Study Baseline in CAT Total Score After Week 52

    Percentage of participants with an improvement of at least 2 points from the parent-study baseline in CAT total score at each scheduled assessment after Week 52.

    Time frame: Up to 36 months

  28. Time to First Moderate or Severe COPD Exacerbation Through End of Study

    Time from initiation of C4531015 study intervention to the first adjudicated moderate or severe COPD exacerbation. The probability of an event will be estimated using the Kaplan-Meier method.

    Time frame: Up to 36 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Supporting information: Study protocol, Statistical analysis plan

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2034, 91 months later.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 91 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 24, 2026
StartEst.
Sep 21, 2026
Primary completionEst.
May 12, 2034
CompletionEst.
May 12, 2034
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07839884
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 24, 2026
Start date
Sep 21, 2026 (estimated)
Primary completion
May 12, 2034 (estimated)
Completion
May 12, 2034 (estimated)
Last update
Sep 24, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tilrekimig

Start the discussion